---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-071974"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:03:53.957134+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q4 revenue up 25% to $114.6M; net income $164.2M; NUZOLVENCE approved

## Summary
- Full year 2025 revenue $411.3M (+15% YoY); net income $271.2M ($4.02 basic EPS).
- Royalty revenue from GSK $250.3M; IST U.S. net product sales $119.2M (+47% YoY).
- FDA approved NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea in Dec 2025.
- Guidance: IST U.S. net product sales at least $150M in 2026.
- $125M repurchase program initiated; 797,298 shares repurchased for $16.0M as of year-end.

## SEC filing metadata
- accession: 0001193125-26-071974
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000119312526071974/0001193125-26-071974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000119312526071974/d23292d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-071974
- JSON: https://secwatch.observer/filing/0001193125-26-071974.json
- Plain text: https://secwatch.observer/filing/0001193125-26-071974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.